Genomic Health (GHDX) Earns Daily Media Sentiment Rating of 0.12

Media coverage about Genomic Health (NASDAQ:GHDX) has been trending somewhat positive recently, according to Accern Sentiment Analysis. The research group identifies negative and positive press coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Genomic Health earned a daily sentiment score of 0.12 on Accern’s scale. Accern also assigned media headlines about the medical research company an impact score of 45.5897141799389 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.

GHDX has been the topic of several research reports. Canaccord Genuity lowered their target price on Genomic Health from $36.00 to $35.00 and set a “buy” rating on the stock in a report on Tuesday, August 15th. BidaskClub raised Genomic Health from a “sell” rating to a “hold” rating in a report on Saturday, August 26th. Cowen reissued a “hold” rating and issued a $34.00 target price on shares of Genomic Health in a report on Friday, September 1st. Jefferies Group reissued a “hold” rating and issued a $33.00 target price on shares of Genomic Health in a report on Thursday, September 14th. Finally, Zacks Investment Research lowered Genomic Health from a “hold” rating to a “sell” rating in a report on Wednesday, October 4th. Two equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and one has assigned a buy rating to the stock. The company has an average rating of “Hold” and a consensus price target of $32.67.

Shares of Genomic Health (NASDAQ:GHDX) opened at $29.82 on Friday. Genomic Health has a 12-month low of $26.37 and a 12-month high of $34.02.

In other news, insider James J. Vaughn sold 1,379 shares of the company’s stock in a transaction on Thursday, November 2nd. The stock was sold at an average price of $32.51, for a total value of $44,831.29. The sale was disclosed in a filing with the SEC, which is available through this link. Also, COO G Bradley Cole sold 5,000 shares of the company’s stock in a transaction on Tuesday, September 12th. The shares were sold at an average price of $31.86, for a total value of $159,300.00. The disclosure for this sale can be found here. Insiders sold 21,379 shares of company stock worth $676,131 over the last 90 days. Company insiders own 46.20% of the company’s stock.

WARNING: This report was first reported by Community Financial News and is the property of of Community Financial News. If you are viewing this report on another website, it was illegally stolen and reposted in violation of US and international copyright and trademark legislation. The correct version of this report can be accessed at https://www.com-unik.info/2017/12/08/genomic-health-ghdx-earns-daily-media-sentiment-rating-of-0-12.html.

About Genomic Health

Genomic Health, Inc is a healthcare company that provides genomic-based diagnostic tests to personalize cancer treatment. The Company develops and commercializes genomic-based clinical laboratory services. The Company’s Oncotype IQ Genomic Intelligence Platform is consisted of its flagship line of Oncotype DX gene expression tests, as well as its Oncotype SEQ Liquid Select test.

Insider Buying and Selling by Quarter for Genomic Health (NASDAQ:GHDX)

What are top analysts saying about Genomic Health Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Genomic Health Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit